Skip to main content
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: AIDS. 2024 Mar 22;38(8):1131–1140. doi: 10.1097/QAD.0000000000003882

Table 2.

Difference in mean levels of Cellular HIV RNA and total HIV DNA outcomes, 7 days after vaccination

Outcome Pneumococcal Vaccine Influenza Vaccine
N Mean (95% CI) p-value* N Mean (95% CI) p-value*
Vaccine Placebo Difference° Vaccine Placebo Difference°
HIV RNAGag 35 −563.9
(−1691.3, 563.4)		 423.8
(−458.9 to 1306.5)		 −987.7
(−2996.1, 1020.6)		 0.33 40 −38.1
(−103.5, 27.4)		 373.5
(−395.2 to 1142.1)		 −411.5
(−1205.3, 382.3)		 0.30
Total HIV DNA 35 −8.2
(−40.3, 23.9)		 −5.4
(−95.8 to 85.0)		 −2.8
(−94.7, 89.1)		 0.95 40 −8.5
(−51.4, 34.5)		 −1.2
(−80.6 to 78.3)		 −7.3
(−67.7, 53.1)		 0.81
HIV DNA 2-LTR 35 −1.7
(−6.9, 3.4)		 1.4
(−6.7 to 9.4)		 −3.1
(−8, 1.8)		 0.20 40 −1.1
(−5.6, 3.5)		 1.3
(−5.8 to 8.4)		 −2.4
(−6.5, 1.7)		 0.25
HIV RNATatRev 35 2.4
(−8.2, 13.1)		 10.7
(−0.3 to 21.7)		 −8.3
(−24.3, 7.7)		 0.30 40 0.5
(−8.7, 9.8)		 8.6
(−1.3 to 18.5)		 −8.1
(−22.1, 6)		 0.25
*

Paired t-test,

°

Vaccine minus placebo, CI = confidence interval